Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LuMend's Breakthrough Break Out

Executive Summary

For many device companies and their investors, drug-eluting stents have come to represent a kind of technological end-game, a device so successful at solving an important unmet need that all future opportunities lie elsewhere. But, in fact, there are still many important unsolved problems in interventional cardiology, not the least of which is chronic total occlusions, lesions so thick and dense that blood can't flow through the artery. That's the problem LuMend has set out to solve and it has the first US-approved device on the market. And while some question the company's timing, LuMend officials argue they couldn't be better timed, since their device and drug-eluting stents go hand in hand.
Advertisement
Advertisement

Related Content

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001917

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel